| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| (loss) income before income tax benefit (expense) | -39,339 | -34,599 | -11,655 | -33,630 |
| Income tax expense (benefit) | - | 172 | - | -420 |
| Net (loss) income | -39,339 | -34,771 | -11,655 | -33,210 |
| Earnings per share, basic | -0.62 | -0.55 | -0.19 | -0.54 |
| Earnings per share, diluted | -0.62 | -0.55 | -0.19 | -0.54 |
| Weighted average number of shares outstanding, basic | 63,772,332 | 63,510,537 | 62,963,806 | 61,767,934 |
| Weighted average number of shares outstanding, diluted | 63,772,332 | 63,510,537 | 62,963,806 | 61,767,934 |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)